This afternoon we watched Insmed drop -3.9% to a price of $62.0 per share. The Large-Cap Pharmaceutical company is now trading -18.71% below its average target price of $76.27. Analysts have set target prices ranging from $60.0 to $90.0 per share for Insmed, and have given the stock an average rating of buy.
Insmed has an average level of shares sold short, at 7.2% of its total share float. The stock's short ratio (also called days to cover) is 2.14. The company's insiders own 1.01% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Institutional investors own 95.2% of Insmed's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Insmed
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Vanguard Group Inc | 10% | 14,509,235 | $899,572,570 |
| 2024-03-31 | Blackrock Inc. | 8% | 11,799,701 | $731,581,462 |
| 2024-03-31 | Price (T.Rowe) Associates Inc | 7% | 10,769,366 | $667,700,692 |
| 2024-03-31 | FMR, LLC | 6% | 9,318,894 | $577,771,428 |
| 2024-03-31 | State Street Corporation | 4% | 5,905,127 | $366,117,874 |
| 2024-03-31 | Deep Track Capital, Lp | 3% | 4,783,679 | $296,588,098 |
| 2024-03-31 | Palo Alto Investors Lp | 3% | 4,423,369 | $274,248,878 |
| 2024-03-31 | William Blair Investment Management, LLC | 3% | 4,214,719 | $261,312,578 |
| 2024-03-31 | Macquarie Group Limited | 3% | 3,899,504 | $241,769,248 |
| 2024-03-31 | Franklin Resources, Inc. | 2% | 3,567,013 | $221,154,806 |
